Impact of Secured Prescription Implementation for Zolpidem on Hypnotics Use in France: A Time-Series Analysis on National Data
| dc.rights.license | open | en_US |
| dc.contributor.author | ROUSSELOT, N. | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | PARIENTE, Antoine
IDREF: 13395711X | |
| hal.structure.identifier | Bordeaux population health [BPH] | |
| dc.contributor.author | MANSIAUX, Yohann | |
| dc.contributor.author | VICTORRI-VIGNEAU, C. | |
| dc.date.accessioned | 2021-02-15T14:13:08Z | |
| dc.date.available | 2021-02-15T14:13:08Z | |
| dc.date.issued | 2020 | |
| dc.identifier.issn | 1544-1709 | en_US |
| dc.identifier.uri | https://oskar-bordeaux.fr/handle/20.500.12278/26248 | |
| dc.description.abstractEn | We evaluated the impact of the implementation of a requirement that zolpidem prescriptions be obtained via secured forms (April 2017) on zolpidem and other hypnotics use in France. We conducted a time-series analysis on data from the French national health care system, from January 1, 2015 to January 3, 2018, for all reimbursed hypnotics. An important and immediate decrease in zolpidem use (−161,873 defined daily doses [DDD]/month; −215,425 to −108,323) was evidenced, with a concomitant raise in zopiclone use (+64,871; +26,925 to +102,817). These findings suggest that the change in zolpidem prescribing policies was effective, but has resulted in a shift from zolpidem to zopiclone. Further interventions are needed to decrease hypnotics’ overuse in France. | |
| dc.language.iso | EN | en_US |
| dc.subject | PharmacoEpi-Drugs | |
| dc.title.en | Impact of Secured Prescription Implementation for Zolpidem on Hypnotics Use in France: A Time-Series Analysis on National Data | |
| dc.title.alternative | Ann Fam Med | en_US |
| dc.type | Article de revue | en_US |
| dc.identifier.doi | 10.1370/afm.2556 | en_US |
| dc.subject.hal | Sciences du Vivant [q-bio]/Santé publique et épidémiologie | en_US |
| dc.identifier.pubmed | 32661036 | en_US |
| bordeaux.journal | Annals of Family Medicine | en_US |
| bordeaux.page | 345-348 | en_US |
| bordeaux.volume | 18 | en_US |
| bordeaux.hal.laboratories | Bordeaux Population Health Research Center (BPH) - U1219 | en_US |
| bordeaux.issue | 4 | en_US |
| bordeaux.institution | Université de Bordeaux | en_US |
| bordeaux.team | PharmacoEpi-Drugs | en_US |
| bordeaux.peerReviewed | oui | en_US |
| bordeaux.inpress | non | en_US |
| hal.identifier | hal-03141784 | |
| hal.version | 1 | |
| hal.date.transferred | 2021-02-15T14:13:11Z | |
| hal.export | true | |
| bordeaux.COinS | ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Annals%20of%20Family%20Medicine&rft.date=2020&rft.volume=18&rft.issue=4&rft.spage=345-348&rft.epage=345-348&rft.eissn=1544-1709&rft.issn=1544-1709&rft.au=ROUSSELOT,%20N.&PARIENTE,%20Antoine&MANSIAUX,%20Yohann&VICTORRI-VIGNEAU,%20C.&rft.genre=article |
Fichier(s) constituant ce document
| Fichiers | Taille | Format | Vue |
|---|---|---|---|
|
Il n'y a pas de fichiers associés à ce document. |
|||